Worth reading
23Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Incoming appointee
78 itemsScheduled Appointment DateEffective 1 October 2026 (the effective date of organizational reforms, changes in executive officers’ responsibilities and personnel changes at multiple subsidiaries)
Mako Kaoru (真子 薫)
Yamagishi Yoshimi (山岸 好)
Norio Hirako (平子 典央)
Osawa Satoshi (大澤 敏)
Tanaka Jun (田中 純)
Yoshikawa Tatsuo (吉川 龍夫)
Sunabu Hiroyoshi (砂生 宏義)
Inoue Akito (井上 朗人)
Kubo Shinji (久保 真二)
Ogata Tsukasa (尾形 司)
Kawai Shingo (河合 真吾)
Hirate Tomoya (平手 智也)
Hyogo Hiroshi (兵庫 洋)
Ono Hiroshi (大野 弘)
Takahashi Tomoki (髙橋 智樹)
Kamiya Yoichi (神谷 陽一)
Nakaoka Shogo (中岡 昇悟)
Sueno Masayasu (末野 将康)
Inoue Masayuki (井上 雅之)
Sato Seiji (佐藤 聖司)
Morikawa Yusuke (森川 裕介)
Nishi Yoshio (西 義夫)
Izumi Tomokazu (泉 友和)
Yamashita Katsushi (山下 勝志)
Sakamoto Hideki (坂本 英紀)
Sasaki Jun (佐々木 淳)
Hatasa Hiroyuki (畑佐 浩之)
Aoshima Ken (青島 研)
Iwabuchi Hajime (岩淵 元)
Kojima Ryo (小嶋 亮)
Watanabe Noriyuki (渡辺 教之)
Murakawa Seiji (村川 清治)
Yoshitani Shinji (吉谷 真二)
Sagawa Yoichiro (佐川 陽一朗)
Maekawa Makoto (前川 信)
Nomoto Giichi (野本 儀一)
Kamano Takahiro (鎌野 孝浩)
Tanioka Toshihiko (谷岡 寿彦)
Tanimoto Mitsuru (谷本 満)
Yamagami Yusuke (山上 祐介)
Joko Shinji (上甲 晋司)
Kondo Hiroyuki (近藤 裕之)
Saeki Naoki (佐伯 尚紀)
Fujii Yoshinori (藤井 儀典)
Shinozaki Masatsugu (篠崎 将継)
Yabe Yuji (矢部 裕二)
Ogami Masashi (大上 雅史)
Yanai Takafumi (柳井 孝文)
Takahashi Masaoki (高橋 正興)
Urata Koji (浦田 幸司)
Kawazoe Keisuke (河添 敬輔)
Watase Maiko (渡瀬 麻衣子)
Kume Masao (久米 政夫)
Akari Hideki (明力 英樹)
Kiriyama Kazuo (桐山 和雄)
Arakaki Yoshihiro (新垣 吉浩)
Koshiba Hiroshi (小柴 浩)
Murasawa Toru (村澤 享)
Morimoto Atsuhiro (森元 敦宏)
Yoshida Kazumasa (吉田 和正)
Takano Tatsuyuki (高野 竜之)
Kameya Takaharu (亀谷 貴治)
Baba Manabu (馬場 学)
Tatezawa Masahiro (舘澤 正宏)
Momozono Koetsu (桃園 幸悦)
Suzuki Naoyuki (鈴木 直之)
Kanno Noboru (菅野 昇)
Kurihara Katsuhiko (栗原 勝彦)
Nakamura Naoto (中村 直人)
Suzuki Akihisa (鈴木 昭寿)
Saito Yuki (齋藤 雄毅)
Abe Masaaki (阿部 正明)
Okubo Hayato (大久保 隼人)
Miwa Nobuhiro (三輪 宣宏)
Musha Ryohei (武捨 良平)
Hayashi Hideki (林 秀樹)
Maeba Masayuki (前場 政幸)
Uetake Kazuyuki (植竹 和之)
Previous positionThe current positions listed in the personnel change tables for each subsidiary
New positionThe new positions listed in the personnel change tables for each subsidiary, including department head, group head, branch manager, director, and executive officer responsibilities
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Details of organizational changes
At アルフレッサ株式会社, the Edogawa Pharmaceutical Center will be abolished, the Medical-Related Planning and Promotion Group will be established, multiple groups will be consolidated and renamed, and branches will be transferred. At 四国アルフレッサ株式会社, the Administration Headquarters will be renamed the Corporate Headquarters, and the Kagawa, Ehime, Tokushima and Kochi Sales Departments will be established, while 2 regional divisions will be abolished. At 株式会社琉薬, 3 departments will be reorganized. At 東北アルフレッサ株式会社, departments and groups will be renamed, the Akita Sales Department and Yamagata Sales Department will be consolidated, 2 groups will be consolidated, and the Hanamaki Logistics Center will be abolished. At アルフレッサ ヘルスケア株式会社, the Wide-Area Fourth Branch will be established, and the Tokyo First Branch and Tokyo Second Branch will be consolidated.
| Item | Details |
|---|---|
| Scheduled Appointment Date | Effective 1 October 2026 (the effective date of organizational reforms, changes in executive officers’ responsibilities and personnel changes at multiple subsidiaries) |
| Name of appointee | Mako Kaoru (真子 薫), Yamagishi Yoshimi (山岸 好), Norio Hirako (平子 典央), Osawa Satoshi (大澤 敏), Tanaka Jun (田中 純), Yoshikawa Tatsuo (吉川 龍夫), Sunabu Hiroyoshi (砂生 宏義), Inoue Akito (井上 朗人), Kubo Shinji (久保 真二), Ogata Tsukasa (尾形 司), Kawai Shingo (河合 真吾), Hirate Tomoya (平手 智也), Hyogo Hiroshi (兵庫 洋), Ono Hiroshi (大野 弘), Takahashi Tomoki (髙橋 智樹), Kamiya Yoichi (神谷 陽一), Nakaoka Shogo (中岡 昇悟), Sueno Masayasu (末野 将康), Inoue Masayuki (井上 雅之), Sato Seiji (佐藤 聖司), Morikawa Yusuke (森川 裕介), Nishi Yoshio (西 義夫), Izumi Tomokazu (泉 友和), Yamashita Katsushi (山下 勝志), Sakamoto Hideki (坂本 英紀), Sasaki Jun (佐々木 淳), Hatasa Hiroyuki (畑佐 浩之), Aoshima Ken (青島 研), Iwabuchi Hajime (岩淵 元), Kojima Ryo (小嶋 亮), Watanabe Noriyuki (渡辺 教之), Murakawa Seiji (村川 清治), Yoshitani Shinji (吉谷 真二), Sagawa Yoichiro (佐川 陽一朗), Maekawa Makoto (前川 信), Nomoto Giichi (野本 儀一), Kamano Takahiro (鎌野 孝浩), Tanioka Toshihiko (谷岡 寿彦), Tanimoto Mitsuru (谷本 満), Yamagami Yusuke (山上 祐介), Joko Shinji (上甲 晋司), Kondo Hiroyuki (近藤 裕之), Saeki Naoki (佐伯 尚紀), Fujii Yoshinori (藤井 儀典), Shinozaki Masatsugu (篠崎 将継), Yabe Yuji (矢部 裕二), Ogami Masashi (大上 雅史), Yanai Takafumi (柳井 孝文), Takahashi Masaoki (高橋 正興), Urata Koji (浦田 幸司), Kawazoe Keisuke (河添 敬輔), Watase Maiko (渡瀬 麻衣子), Kume Masao (久米 政夫), Akari Hideki (明力 英樹), Kiriyama Kazuo (桐山 和雄), Arakaki Yoshihiro (新垣 吉浩), Koshiba Hiroshi (小柴 浩), Murasawa Toru (村澤 享), Morimoto Atsuhiro (森元 敦宏), Yoshida Kazumasa (吉田 和正), Takano Tatsuyuki (高野 竜之), Kameya Takaharu (亀谷 貴治), Baba Manabu (馬場 学), Tatezawa Masahiro (舘澤 正宏), Momozono Koetsu (桃園 幸悦), Suzuki Naoyuki (鈴木 直之), Kanno Noboru (菅野 昇), Kurihara Katsuhiko (栗原 勝彦), Nakamura Naoto (中村 直人), Suzuki Akihisa (鈴木 昭寿), Saito Yuki (齋藤 雄毅), Abe Masaaki (阿部 正明), Okubo Hayato (大久保 隼人), Miwa Nobuhiro (三輪 宣宏), Musha Ryohei (武捨 良平), Hayashi Hideki (林 秀樹), Maeba Masayuki (前場 政幸), Uetake Kazuyuki (植竹 和之) |
| Appointee's new position | The new positions listed in the personnel change tables for each subsidiary, including department head, group head, branch manager, director, and executive officer responsibilities |
| Appointee's previous position | The current positions listed in the personnel change tables for each subsidiary |
| Details of organizational changes | At アルフレッサ株式会社, the Edogawa Pharmaceutical Center will be abolished, the Medical-Related Planning and Promotion Group will be established, multiple groups will be consolidated and renamed, and branches will be transferred. At 四国アルフレッサ株式会社, the Administration Headquarters will be renamed the Corporate Headquarters, and the Kagawa, Ehime, Tokushima and Kochi Sales Departments will be established, while 2 regional divisions will be abolished. At 株式会社琉薬, 3 departments will be reorganized. At 東北アルフレッサ株式会社, departments and groups will be renamed, the Akita Sales Department and Yamagata Sales Department will be consolidated, 2 groups will be consolidated, and the Hanamaki Logistics Center will be abolished. At アルフレッサ ヘルスケア株式会社, the Wide-Area Fourth Branch will be established, and the Tokyo First Branch and Tokyo Second Branch will be consolidated. |
Items this document does not state (16)
Resolution dateDate of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The notice states that organizational reforms and changes in executive officers and personnel will be implemented, but does not provide specific reasons for doing so.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.